Cancer and Hematology Center, Texas Children's Hospital, Houston, Texas.
Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Pediatr Blood Cancer. 2021 Mar;68(3):e28778. doi: 10.1002/pbc.28778. Epub 2020 Oct 21.
Central giant cell granuloma (CGCG) is a benign but locally aggressive intraosseous lesion of the mandible. Historically, it is treated by curettage or resection. Medical therapy is indicated when surgery is associated with increased morbidity or in adjuvant setting to decrease recurrence. Treatment of CGCG with denosumab, a receptor activator of nuclear factor kappa-beta (RANK) ligand inhibitor, is not well studied, especially in children. Here, we describe our experience with the use of denosumab in the treatment of six children with CGCG. All patients had a favorable response with manageable side effects, which suggests that denosumab is an effective treatment option without increased morbidity.
中央性 giant 细胞肉芽肿（CGCG）是下颌骨的一种良性但局部侵袭性的骨内病变。历史上，它通过刮除术或切除术治疗。当手术与增加发病率相关或在辅助治疗以降低复发率时，需要进行药物治疗。用 denosumab（核因子 kappa-beta（RANK）配体抑制剂的受体激活剂）治疗 CGCG 的研究并不充分，特别是在儿童中。在这里，我们描述了使用 denosumab 治疗六名 CGCG 儿童的经验。所有患者均有良好的反应，且副作用可控制，这表明 denosumab 是一种有效的治疗选择，不会增加发病率。
